Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2025)
Historic Common Equity for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $332.0 million.
- Amylyx Pharmaceuticals' Common Equity rose 6921.05% to $332.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $332.0 million, marking a year-over-year increase of 6921.05%. This contributed to the annual value of $164.8 million for FY2024, which is 6198.6% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Common Equity stood at $332.0 million for Q3 2025, which was up 6921.05% from $167.9 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' Common Equity's 5-year high stood at $433.4 million during Q4 2023, with a 5-year trough of -$151.2 million in Q4 2021.
- In the last 5 years, Amylyx Pharmaceuticals' Common Equity had a median value of $251.1 million in 2022 and averaged $250.4 million.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Common Equity soared by 32531.69% in 2022, and later plummeted by 6198.6% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Common Equity stood at -$151.2 million in 2021, then skyrocketed by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then tumbled by 61.99% to $164.8 million in 2024, then skyrocketed by 101.5% to $332.0 million in 2025.
- Its Common Equity stands at $332.0 million for Q3 2025, versus $167.9 million for Q2 2025 and $201.4 million for Q1 2025.